SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-062241
Filing Date
2024-03-07
Accepted
2024-03-07 16:31:09
Documents
16
Period of Report
2024-03-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d764198d8k.htm   iXBRL 8-K 25027
2 EX-99.1 d764198dex991.htm EX-99.1 4007
6 GRAPHIC g764198g0307074350948.jpg GRAPHIC 4002
  Complete submission text file 0001193125-24-062241.txt   158486

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20240306.xsd EX-101.SCH 2888
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20240306_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20240306_pre.xml EX-101.PRE 11286
17 EXTRACTED XBRL INSTANCE DOCUMENT d764198d8k_htm.xml XML 3652
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 24730620
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)